STN1014003 ophthalmic solution in patients with open-angle glaucoma/ocular hypertension phase III study
Recruiting
- Conditions
- open angle glaucoma (OAG) or ocular hypertension (OHT)
- Registration Number
- jRCT2031240688
- Lead Sponsor
- Santen pharmaceutical co.,ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 230
Inclusion Criteria
- 18 years of age or older.
- Diagnosis of OAG or OHT in both eyes
- Best corrected visual acuity (BCVA) in any eye is 0.20 or better in decimal visual acuity
- Willingness and ability to give signed informed consent and follow study instructions
Exclusion Criteria
- Clinically significant ocular disease
- History of angle closure glaucoma, or narrow angles
- Previous glaucoma intraocular surgery
- Clinically significant systemic disease
- Participation in any investigational study within 30 days prior to screening
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - Mean diurnal IOP at Week 4
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does STN1014003 target in open-angle glaucoma and ocular hypertension?
How does STN1014003 compare to latanoprost in reducing intraocular pressure for OAG/OHT patients?
Are there specific biomarkers that predict response to STN1014003 in glaucoma treatment?
What adverse events are associated with STN1014003 versus latanoprost in glaucoma management?
What are the potential combination therapies involving STN1014003 for open-angle glaucoma?